Back to trial

NCT02576431

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Version 47 to 48 · Bayer

Patch inspector

Version 47 to 48

29 operations 4 path groups ctgov_internal_history
ClinicalTrials.gov
Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.
Plain-language summary

Manual review pending.

Rules fired
eligibility_criteria_changeenrollment_count_change
Value signals

None recorded.

Provenance
Source
ctgov_internal_history
Fetched
2026-06-18 19:12:25+00
Raw hash
95110fe9e106c18d190f163b6ff8e6de6285bd69a0ab75e7e9fceed9ba24526c
Payload
Source URL
Design Trial model, phase, allocation, masking, arms, or interventions. Triage: High 1 ops
replace /protocolSection/designModule/enrollmentInfo/count
Triage: High
Enrollment Change Operation 4
Matched rules
  • enrollment_count_change Enrollment count changes can signal scope or feasibility shifts.
Before
203
After
200
Eligibility Criteria and population definition changes. Triage: High 3 ops
replace /protocolSection/eligibilityModule/eligibilityCriteria
Triage: High
Eligibility Change Operation 5
Matched rules
  • eligibility_criteria_change Eligibility criteria changes can alter the studied population.
Before
<p>Inclusion Criteria:</p><ul><li>Locally-advanced or metastatic malignancy with an NTRK1, NTRK2, or NTRK3 gene fusion identified through molecular assays</li><li>Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy</li><li>Subjects must have at least one measurable lesion as defined by RECIST v1.1</li></ul><p>Exclusion Criteria:</p><ul><li>Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK.
Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible.</li><li>Symptomatic or unstable brain metastases.
(Note: Subjects with asymptomatic brain metastases are eligible to participate in the study.)
Subjects with primary CNS tumors are eligible.</li><li>Active uncontrolled systemic bacterial, viral, or fungal infection, unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures.</li><li>Pregnancy or lactation.</li></ul>
After
<p>Inclusion Criteria:</p><ul><li>Locally advanced or metastatic non-secretory breast cancer, lung cancer, melanoma, and colorectal cancer with unknown human neurotrophic tyrosine receptor kinase 1 (NTRK1), NTRK2, or NTRK3 fusion status.</li><li>Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy.</li><li>Subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</li></ul><p>Exclusion Criteria:</p><ul><li>Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting tropomyosin receptor kinase (TRK).
Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible.</li><li>Symptomatic or unstable brain metastases.
(Note: Subjects with asymptomatic brain metastases are eligible to participate in the study.)
Subjects with primary central nervous system (CNS) tumors are eligible.</li><li>Pregnancy or lactation.</li><li>Active uncontrolled systemic bacterial, viral, or fungal infection Common Terminology Criteria for Adverse Events(CTCAE) grade ≥ 2; unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures.</li></ul><p>Unstable cardiovascular disease is defined as:</p><ul><li>In adults, persistently uncontrolled hypertension defined as systolic blood pressure (BP) &gt; 150 mmHg and&#x2F;or diastolic BP &gt; 100 mmHg despite antihypertensive therapy.</li><li>Myocardial infarction within 3 months of screening.</li><li>Stroke within 3 months of screening.</li></ul>
replace /protocolSection/eligibilityModule/minimumAge
Triage: Uncategorized
Uncategorized Operation 6
Before
12 Years
After
18 Years
remove /protocolSection/eligibilityModule/stdAges/0
Triage: Uncategorized
Uncategorized Operation 7
Before
CHILD
Contacts and locations Site, contact, and location updates that are usually operational. Triage: Uncategorized 22 ops
replace /protocolSection/contactsLocationsModule/locations/18/city
Triage: Uncategorized
Uncategorized Operation 8
Before
Buenos Aires
After
Argentina
replace /protocolSection/contactsLocationsModule/locations/18/geoPoint/lat
Triage: Uncategorized
Uncategorized Operation 9
Before
-34.61315
After
-29.53532
replace /protocolSection/contactsLocationsModule/locations/18/geoPoint/lon
Triage: Uncategorized
Uncategorized Operation 10
Before
-58.37723
After
-62.26693
replace /protocolSection/contactsLocationsModule/locations/42/status
Triage: Uncategorized
Uncategorized Operation 11
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/47/facility
Triage: Uncategorized
Uncategorized Operation 12
Before
London Health Sciences Centre
After
London Regional Cancer Program, London Health Sciences Ctr
replace /protocolSection/contactsLocationsModule/locations/47/zip
Triage: Uncategorized
Uncategorized Operation 13
Before
N6A 5A5
After
N6A 5W9
replace /protocolSection/contactsLocationsModule/locations/66/status
Triage: Uncategorized
Uncategorized Operation 14
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/71/status
Triage: Uncategorized
Uncategorized Operation 15
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/76/status
Triage: Uncategorized
Uncategorized Operation 16
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/79/status
Triage: Uncategorized
Uncategorized Operation 17
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/88/facility
Triage: Uncategorized
Uncategorized Operation 18
Before
St. Vincent&#x27;s University Hospital
After
St Vincents University Hospital
replace /protocolSection/contactsLocationsModule/locations/88/zip
Triage: Uncategorized
Uncategorized Operation 19
Before
D04 T6F4
After
DUBLIN 4
replace /protocolSection/contactsLocationsModule/locations/89/status
Triage: Uncategorized
Uncategorized Operation 20
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/90/status
Triage: Uncategorized
Uncategorized Operation 21
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/96/status
Triage: Uncategorized
Uncategorized Operation 22
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/97/status
Triage: Uncategorized
Uncategorized Operation 23
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/104/status
Triage: Uncategorized
Uncategorized Operation 24
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/112/status
Triage: Uncategorized
Uncategorized Operation 25
Before
NOT_YET_RECRUITING
After
WITHDRAWN
replace /protocolSection/contactsLocationsModule/locations/142/status
Triage: Uncategorized
Uncategorized Operation 26
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/144/status
Triage: Uncategorized
Uncategorized Operation 27
Before
NOT_YET_RECRUITING
After
RECRUITING
replace /protocolSection/contactsLocationsModule/locations/147/status
Triage: Uncategorized
Uncategorized Operation 28
Before
NOT_YET_RECRUITING
After
RECRUITING
add /protocolSection/contactsLocationsModule/locations/148
Triage: Uncategorized
Uncategorized Operation 29
After
{
  "zip": "03022",
  "city": "Kiev",
  "status": "NOT_YET_RECRUITING",
  "country": "Ukraine",
  "facility": "National Cancer Institute",
  "geoPoint": {
    "lat": 50.45466,
    "lon": 30.5238
  }
}
Other registry fields Changes outside the current high-signal rule families. Triage: Uncategorized 3 ops
replace /protocolSection/statusModule/statusVerifiedDate
Triage: Uncategorized
Uncategorized Operation 1
Before
2021-04
After
2021-05
replace /protocolSection/statusModule/lastUpdateSubmitDate
Triage: Uncategorized
Uncategorized Operation 2
Before
2021-04-16
After
2021-05-27
replace /protocolSection/statusModule/lastUpdatePostDateStruct/date
Triage: Uncategorized
Uncategorized Operation 3
Before
2021-04-19
After
2021-05-28
Raw JSON Patch
[
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/statusVerifiedDate",
    "value": "2021-05"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2021-05-27"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2021-05-28"
  },
  {
    "op": "replace",
    "path": "/protocolSection/designModule/enrollmentInfo/count",
    "value": 200
  },
  {
    "op": "replace",
    "path": "/protocolSection/eligibilityModule/eligibilityCriteria",
    "value": "<p>Inclusion Criteria:</p><ul><li>Locally advanced or metastatic non-secretory breast cancer, lung cancer, melanoma, and colorectal cancer with unknown human neurotrophic tyrosine receptor kinase 1 (NTRK1), NTRK2, or NTRK3 fusion status.</li><li>Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy.</li><li>Subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</li></ul><p>Exclusion Criteria:</p><ul><li>Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting tropomyosin receptor kinase (TRK).\nSubjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible.</li><li>Symptomatic or unstable brain metastases.\n(Note: Subjects with asymptomatic brain metastases are eligible to participate in the study.)\nSubjects with primary central nervous system (CNS) tumors are eligible.</li><li>Pregnancy or lactation.</li><li>Active uncontrolled systemic bacterial, viral, or fungal infection Common Terminology Criteria for Adverse Events(CTCAE) grade ≥ 2; unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures.</li></ul><p>Unstable cardiovascular disease is defined as:</p><ul><li>In adults, persistently uncontrolled hypertension defined as systolic blood pressure (BP) &gt; 150 mmHg and&#x2F;or diastolic BP &gt; 100 mmHg despite antihypertensive therapy.</li><li>Myocardial infarction within 3 months of screening.</li><li>Stroke within 3 months of screening.</li></ul>"
  },
  {
    "op": "replace",
    "path": "/protocolSection/eligibilityModule/minimumAge",
    "value": "18 Years"
  },
  {
    "op": "remove",
    "path": "/protocolSection/eligibilityModule/stdAges/0"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/18/city",
    "value": "Argentina"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/18/geoPoint/lat",
    "value": -29.53532
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/18/geoPoint/lon",
    "value": -62.26693
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/42/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/47/facility",
    "value": "London Regional Cancer Program, London Health Sciences Ctr"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/47/zip",
    "value": "N6A 5W9"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/66/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/71/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/76/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/79/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/88/facility",
    "value": "St Vincents University Hospital"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/88/zip",
    "value": "DUBLIN 4"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/89/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/90/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/96/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/97/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/104/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/112/status",
    "value": "WITHDRAWN"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/142/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/144/status",
    "value": "RECRUITING"
  },
  {
    "op": "replace",
    "path": "/protocolSection/contactsLocationsModule/locations/147/status",
    "value": "RECRUITING"
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/148",
    "value": {
      "zip": "03022",
      "city": "Kiev",
      "status": "NOT_YET_RECRUITING",
      "country": "Ukraine",
      "facility": "National Cancer Institute",
      "geoPoint": {
        "lat": 50.45466,
        "lon": 30.5238
      }
    }
  }
]